Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Long-term follow-up of foamy viral vector-mediated gene therapy for canine leukocyte adhesion deficiency.

Bauer TR Jr, Tuschong LM, Calvo KR, Shive HR, Burkholder TH, Karlsson EK, West RR, Russell DW, Hickstein DD.

Mol Ther. 2013 May;21(5):964-72. doi: 10.1038/mt.2013.34. Epub 2013 Mar 26.

2.

Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors.

Bauer TR Jr, Allen JM, Hai M, Tuschong LM, Khan IF, Olson EM, Adler RL, Burkholder TH, Gu YC, Russell DW, Hickstein DD.

Nat Med. 2008 Jan;14(1):93-7. Epub 2007 Dec 23.

3.

Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter.

Bauer TR Jr, Olson EM, Huo Y, Tuschong LM, Allen JM, Li Y, Burkholder TH, Russell DW.

Gene Ther. 2011 Jun;18(6):553-9. doi: 10.1038/gt.2010.169. Epub 2011 Jan 13.

4.

Gene therapy of canine leukocyte adhesion deficiency using lentiviral vectors with human CD11b and CD18 promoters driving canine CD18 expression.

Hunter MJ, Tuschong LM, Fowler CJ, Bauer TR Jr, Burkholder TH, Hickstein DD.

Mol Ther. 2011 Jan;19(1):113-21. doi: 10.1038/mt.2010.203. Epub 2010 Sep 21.

5.

Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters.

Hunter MJ, Zhao H, Tuschong LM, Bauer TR Jr, Burkholder TH, Persons DA, Hickstein DD.

Hum Gene Ther. 2011 Jun;22(6):689-96. doi: 10.1089/hum.2010.130. Epub 2011 Apr 11.

6.

Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy.

Bauer TR Jr, Hai M, Tuschong LM, Burkholder TH, Gu YC, Sokolic RA, Ferguson C, Dunbar CE, Hickstein DD.

Blood. 2006 Nov 15;108(10):3313-20. Epub 2006 Jul 25.

7.

Lentiviral vectors incorporating a human elongation factor 1alpha promoter for the treatment of canine leukocyte adhesion deficiency.

Nelson EJ, Tuschong LM, Hunter MJ, Bauer TR Jr, Burkholder TH, Hickstein DD.

Gene Ther. 2010 May;17(5):672-7. doi: 10.1038/gt.2010.7. Epub 2010 Feb 18.

8.

Potential genotoxicity from integration sites in CLAD dogs treated successfully with gammaretroviral vector-mediated gene therapy.

Hai M, Adler RL, Bauer TR Jr, Tuschong LM, Gu YC, Wu X, Hickstein DD.

Gene Ther. 2008 Jul;15(14):1067-71. doi: 10.1038/gt.2008.52. Epub 2008 Mar 27.

PMID:
18369320
10.

Nonmyeloablative hematopoietic stem cell transplantation corrects the disease phenotype in the canine model of leukocyte adhesion deficiency.

Bauer TR Jr, Gu YC, Tuschong LM, Burkholder T, Bacher JD, Starost MF, Donahue RE, Sokolic RA, Hickstein DD.

Exp Hematol. 2005 Jun;33(6):706-12.

PMID:
15911095
11.

Very low levels of donor CD18+ neutrophils following allogeneic hematopoietic stem cell transplantation reverse the disease phenotype in canine leukocyte adhesion deficiency.

Bauer TR Jr, Creevy KE, Gu YC, Tuschong LM, Donahue RE, Metzger ME, Embree LJ, Burkholder T, Bacher JD, Romines C, Thomas ML 3rd, Colenda L, Hickstein DD.

Blood. 2004 May 1;103(9):3582-9. Epub 2004 Jan 8.

12.

Conversion of the severe to the moderate disease phenotype with donor leukocyte microchimerism in canine leukocyte adhesion deficiency.

Gu YC, Bauer TR, Sokolic RA, Hai M, Tuschong LM, Burkholder T, Bacher J, Starost MF, Hickstein DD.

Bone Marrow Transplant. 2006 Mar;37(6):607-14.

PMID:
16444276
13.

Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency.

Trobridge GD, Beard BC, Wu RA, Ironside C, Malik P, Kiem HP.

PLoS One. 2012;7(9):e45173. doi: 10.1371/journal.pone.0045173. Epub 2012 Sep 13. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/90f278b2-f474-42ec-8645-435f7006018c.

14.

Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency.

Sokolic RA, Bauer TR, Gu YC, Hai M, Tuschong LM, Burkholder T, Colenda L, Bacher J, Starost MF, Hickstein DD.

Biol Blood Marrow Transplant. 2005 Oct;11(10):755-63.

15.

Tracking of specific integrant clones in dogs treated with foamy virus vectors.

Ohmine K, Li Y, Bauer TR Jr, Hickstein DD, Russell DW.

Hum Gene Ther. 2011 Feb;22(2):217-24. doi: 10.1089/hum.2010.072. Epub 2010 Dec 19.

16.

Large animal models for foamy virus vector gene therapy.

Trobridge GD, Horn PA, Beard BC, Kiem HP.

Viruses. 2012 Dec 7;4(12):3572-88. doi: 10.3390/v4123572. Review.

17.

Canine leukocyte adhesion deficiency colony for investigation of novel hematopoietic therapies.

Creevy KE, Bauer TR Jr, Tuschong LM, Embree LJ, Colenda L, Cogan K, Starost MF, Haskins ME, Hickstein DD.

Vet Immunol Immunopathol. 2003 Jul 15;94(1-2):11-22.

PMID:
12842608
18.

Mixed chimeric hematopoietic stem cell transplant reverses the disease phenotype in canine leukocyte adhesion deficiency.

Creevy KE, Bauer TR Jr, Tuschong LM, Embree LJ, Silverstone AM, Bacher JD, Romines C, Garnier J, Thomas ML 3rd, Colenda L, Hickstein DD.

Vet Immunol Immunopathol. 2003 Oct 15;95(3-4):113-21.

PMID:
12963272
19.

Foamy-virus-mediated gene transfer to canine repopulating cells.

Kiem HP, Allen J, Trobridge G, Olson E, Keyser K, Peterson L, Russell DW.

Blood. 2007 Jan 1;109(1):65-70. Epub 2006 Sep 12.

20.

Foamy virus vector-mediated gene correction of a mouse model of Wiskott-Aldrich syndrome.

Uchiyama T, Adriani M, Jagadeesh GJ, Paine A, Candotti F.

Mol Ther. 2012 Jun;20(6):1270-9. doi: 10.1038/mt.2011.282. Epub 2012 Jan 3.

Supplemental Content

Support Center